EUVIMEDEUVIMED entdecken
Crossref

Therapeutic potential of infliximab for pruritus in mice model of cholestasis induced by bile duct ligation: Possible involvement of IL-31

Zahra Ebrahim Soltani, Mohammad Elahi, Mohammadmahdi Khavandi, Nazgol-Sadat Haddadi, Maryam Shayan, Mina Khalilzadeh, Ahmad Reza Dehpour

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110806 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Zahra Ebrahim Soltani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran; Research Center for Advanced Technologies in Cardiovascul…. Hauptthemen laut MEDLINE: Tumor Necrosis Factor-alpha, Cholestasis. Die Arbeit nennt 57 Literaturangaben. Gefördert von: Iran National Science Foundation, Tehran University of Medical Sciences and Health Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cholestatic pruritus is a distressful sensation that can cause a massive desire of scratching skin. Despite maximum medication therapy, some patients still experience pruritus. In this study, we evaluated the effect of infliximab on cholestatic pruritus induced in mice by bile duct ligation. METHODS: Twenty-four balb/c mice were randomly assigned to three groups; sham, control, and treatment. The bile duct ligation procedure was performed on mice in the control and treatment groups. After six days, mice in the treatment group received subcutaneous administration of infliximab, and the next day all mice were subjected to the scratching behavior test. Skin, dorsal root ganglia (DRG), and blood samples of mice were collected and evaluated by histopathological, molecular, and biochemical tests. RESULTS: The scratching behavior has significantly decreased in mice with cholestasis after the administration of infliximab. The levels of TNFα, TNFR1, TNFR2, NF-κB, and IL-31were higher in control mice compared to sham. In addition, expression levels of TNFR1, NF-κB, and IL-31 were decreased in the treatment group compared to the controls in skin and DRG, while TNFR2 levels were decreased only in DRG. CONCLUSION: Infliximab can block TNFα interaction with receptors and inhibit further inflammatory response. Also, our results suggested that infliximab can suppress IL-31 expression indirectly, which is a well-known cytokine in pruritus pathophysiology Infliximab can be a potential therapeutic approach in resistant pruritus in cholestatic disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Necrosis Factor-alphaCholestasisHumansAnimalsMiceInfliximabReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IINF-kappa BBile DuctsPruritusDisease Models, Animal

Stichwörter der Autor:innen

Bile duct ligationCholestasisIL-3InfliximabPruritusTNFα

Substanzen

InfliximabTumor Necrosis Factor-alphaReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IINF-kappa B

Autor:innen und Institutionen

  • Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran; Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Dermatology, UMass Chan Medical School, Worcester, MA, USA.
  • Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: dehpour@yahoo.com.

Förderung

  • Iran National Science Foundation
  • Tehran University of Medical Sciences and Health Services

Zitieren

APA

Ebrahim Soltani, Z., Elahi, M., Khavandi, M., Haddadi, N. S., Shayan, M., Khalilzadeh, M., & Dehpour, A. R. (2023). Therapeutic potential of infliximab for pruritus in mice model of cholestasis induced by bile duct ligation: Possible involvement of IL-31. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110806

Vancouver

Ebrahim Soltani Z, Elahi M, Khavandi M, Haddadi NS, Shayan M, Khalilzadeh M, et al. Therapeutic potential of infliximab for pruritus in mice model of cholestasis induced by bile duct ligation: Possible involvement of IL-31. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110806

BibTeX
@article{EbrahimSoltani2023,
  author = {Ebrahim Soltani, Zahra and Elahi, Mohammad and Khavandi, Mohammadmahdi and Haddadi, Nazgol-Sadat and Shayan, Maryam and Khalilzadeh, Mina and Dehpour, Ahmad Reza},
  title = {Therapeutic potential of infliximab for pruritus in mice model of cholestasis induced by bile duct ligation: Possible involvement of IL-31},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110806}
}
Kostenlos starten →